In the past few years, Europe, the US and, more recently, Australia, have noted an increase in the diagnosis of sexually transmitted acute HCV infections among homosexual HIV-positive patients [1] [2] [3] [4] [5] [6] [7] . The epidemic is ongoing [8] and, given the low rate of spontaneous HCV clearance in HIV-positive patients [9, 10] , specific treatment for HCV infection is usually required. Although several controlled trials have been performed on non-HIV patients in order to refine anti-HCV treatment and excellent response rates in up to 98% of patients have been observed, currently, optimal timing, type and length of interferon therapy for HIV-infected patients remain controversial as data have been limited to small pilot studies and cohorts.
In the past few years, Europe, the US and, more recently, Australia, have noted an increase in the diagnosis of sexually transmitted acute HCV infections among homosexual HIV-positive patients [1] [2] [3] [4] [5] [6] [7] . The epidemic is ongoing [8] and, given the low rate of spontaneous HCV clearance in HIV-positive patients [9, 10] , specific treatment for HCV infection is usually required. Although several controlled trials have been performed on non-HIV patients in order to refine anti-HCV treatment and excellent response rates in up to 98% of patients have been observed, currently, optimal timing, type and length of interferon therapy for HIV-infected patients remain controversial as data have been limited to small pilot studies and cohorts.
In order to evaluate factors associated with sustained virological response (SVR) after HCV therapy, we conducted this multicentre observational study.
Methods
All consecutive HIV-positive individuals with acute HCV infection who had received anti-HCV treatment as part of one of four prospective clinical cohorts were included in this multicentre observational cohort 2, 5 , Christine Katlama 2, 5 , Jürgen K Rockstroh 1 
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Introduction study between 2001 and 2006. Screening for acute HCV was performed in all patients presenting with an unexplained increase of liver enzymes on routine 3-monthly follow-ups of HIV infection and who had a recent history of exposure to HCV and/or clinical signs or symptoms of hepatitis (including jaundice, severe asthaenia and discolouring of urine and stool). Inclusion criteria and treatment protocol differed among the cohorts (Table 1 ). Treatment outcome of these patients had been previously published in part for three of the four clinical trials [1, 3, 11] . Treatments for reinfections were excluded from this analysis. Pegylated interferon (PEG-IFN)-α2a (180 µg once weekly) or PEG-IFN-α2b (1.5 µg/kg bodyweight once weekly) were given to all patients; ribavirin use, dosage and planned treatment duration were dependent on the local protocol (Table 1) .
Patients were included in the study after providing written informed consent. The studies were conducted in agreement with good clinical practice and the Declaration of Helsinki and its subsequent revisions, and had been approved by the respective local ethics committee.
Methods
The primary end point was the proportion of patients who maintained an SVR defined as negative HCV RNA levels in plasma 24 weeks after anti-HCV treatment discontinuation. HCV RNA was measured locally and a common detection limit was set at 600 IU/ml, that is, HCV RNA levels <600 IU/ml were considered as HCV-RNA-negative. We performed a statistical analysis to investigate whether basic demographics, host-virus interaction, HCV-, HIV-or treatmentrelated characteristics had any effect on SVR.
Secondary end points included the proportion of patients with undetectable HCV RNA at week 4 (rapid virological response [RVR]), at week 12 (early virological response [EVR] ) and at the end of treatment (EOT), evolution of CD4 + T-cell count and tolerability of treatment. Analyses were performed with missing data categorized as failure to classify response to treatment. Comparisons between groups were performed using Mann-Whitney U, Wilcoxon or Fisher's exact tests. A P-value of <0.05 was considered as significant.
Results
Baseline patient characteristics
A total of 150 HIV-infected men experienced a first episode of acute HCV infection between 2001 and 2006. Of these, 39 patients did not receive treatment because of refusal (n=25) or negative HCV RNA 12 weeks after diagnosis (n=14). Overall, 11/39 (28%) of the untreated patients remained HCV-RNA-negative at 48 weeks after diagnosis. Of the 14 patients who reached a negative HCV RNA within 12 weeks after diagnosis, 3 turned positive and had a chronic course of HCV infection. A total of 111 patients received at least one dose of PEG-IFN and/or ribavirin and were considered for analysis. All were male with a mean age of 38 years and were having sex with men ( Table 2 ). The risk factor for acquisition of HCV was sexual intercourse in all but 2 individuals who were intravenous drug users and 11 in whom the route of HCV infection remained unknown. The definition of acute HCV within European cohorts is HCV-RNA-positive, increased liver function tests and documented past negative anti-HCV antibody test. In France, patients with alanine aminotransferase (ALT) levels ≥3× the upper limit of normal (ULN) were evaluated for acute HCV and diagnosed if anti-HCV antibody test was negative within the past 6 months. For the Chelsea and Westminister Hospital (UK-CHW), patients with increased ALT or history of sexual exposure to known HCV-positive partners were evaluated for acute HCV and diagnosed if anti-HCV antibody test was negative within the past 6 months. In the Royal Free Hospital (UK-RFH), patients with an increase of ALT levels, a history of a recent sexually transmitted infection or known exposure to HCV were evaluated and diagnosed if anti-HCV antibody test was negative within the past 12 months. In Germany, acute HCV infection was defined by two of three criteria within the past 4 months: transmission risk factor, ALT>350 IU/l with normal transaminases during the year before infection or anti-HCV seroconversion. Within the original protocol, 24 weeks of pegylated interferon (PEG-IFN) was given to all patients. The protocol was amended twice throughout the trial. After amendment I, patients with genotype 1 or 4 infections were administrated weight-adapted ribavirin (RBV) in addition to PEG-IFN treatment. After amendment II, patients with symptomatic acute HCV infection were observed for 12 weeks after diagonosis of acute HCV and treatment was only recommended for those patients in whom HCV RNA levels had not signicantly decreased.
Treatment
Patients started treatment according to local protocols within the cohorts. Treatment was started at a median of 12 weeks (interquartile range [IQR] 5-20) after diagnosis of acute HCV infection. There were 18 patients who started treatment later than 24 weeks after diagnosis of acute HCV. Overall, 97 (87%) patients received a combination of PEG-IFN and ribavirin and 14 (13%) patients were treated with PEG-IFN monotherapy. Of those receiving PEG-IFN and ribavirin, 76 (78%) received weight-adapted (1,000 or 1,200 mg/day) ribavirin. Nine (8%) patients received treatment for only 12 weeks (one patient was lost to follow-up, one lacked EVR and seven experienced toxicity).
Virological response to hepatitis C therapy
An EOT response was reached in 84 (76%) patients (95% confidence interval [CI] 67-83), which was sustained (SVR) in 69 (62%) patients (95% CI 52-71). Initial virological responses were strong predictors for SVR. At week 4, 42 (38%) patients had negative HCV RNA levels (RVR), which translated into SVR in 39 patients (positive predictive value 93%; Table 3 ). In contrast to the 69 patients without RVR, an SVR was observed in only 30 (43%) patients. At week 12, 78 (70%) patients had a negative HCV RNA level (EVR) and SVR was reached in 66 (85%) patients. By contrast, only 3 of the 33 (9%) patients with a positive HCV RNA at week 12 achieved SVR (negative predictive value 91%). We investigated whether demographics, or host-virus interaction, host-, HCV-, HIV-or treatmentrelated factors had any influence on treatment outcome. None of the examined factors proved to be statistically significant ( Table 4) .
Safety of anti-HCV therapy
Overall, 36 (32%) patients experienced a moderate to severe (WHO grade 3 or 4) treatment-related adverse event (psychiatric n=12, haematological n=10, liver transaminases n=4 and other n=10). A total of 12 patients had to stop treatment because of toxicity (psychiatric n=6, liver transaminases n=2, haematological n=1, loss of body weight n=1, general tolerability n=1 and lethargy n=1) and 5 additional patients needed a dose reduction of ribavirin or PEG-IFN. Throughout anti-HCV treatment, no fatalities and no opportunistic infections were observed.
A median decrease of 105 absolute CD4 + T-cells/ml caused by the haematotoxic side effect of PEG-IFN therapy was noted (median variation/baseline -105 [IQR -213--28]); however, baseline values were regained at 24 weeks after the EOT (median variation/baseline -15 [IQR -102-37]).
Discussion
Sexually acquired acute HCV infection is an ongoing epidemic among HIV-positive men who have sex with men in European metropolitan cities [12] . Following early treatment of acute HCV infection in HIV-positive individuals, we observed SVR rates in 62% of patients, which is similar to data reported by other groups [6, 7] . Importantly, the rate is far higher than the rate of spontaneous resolution observed, and also higher than that observed in the setting of chronic HCV infection, in particular recognizing the high rate of genotype 1 infections in our cohort [13] [14] [15] . Despite accumulating treatment data, questions remain as to how best to treat our patients.
Employing a watch-and-wait strategy, 14 patients were HCV-RNA-negative at 12 weeks after diagnosis, yet 3 turned HCV-RNA-positive during further follow-up. Unfortunately, in our study, no phylogenetic sampling was undertaken to securely differentiate between a relapse of a new infection. In any case, continued monitoring of liver transaminases and or HCV RNA appears advisable in order not to overlook a relapse or reinfection.
Although it was a small study and underpowered to answer this question, in a previous study of the German Cohort [11] , patients treated with PEG-IFN monotherapy achieved a higher SVR rate than patients treated with PEG-IFN plus ribavirin therapy (73% versus 38%) and with 48 weeks than with 24 weeks of therapy (89% versus 52%). Despite a large patient sample, our study still did not reach statistical power to draw strong conclusions on the use of ribavirin or duration of therapy. Given the low numbers of patients within each subset of treatment modality and the observational nature of the cohort, our findings with regard to these end points must therefore be taken with caution.
We were, however, able to show, that the decay of HCV RNA under treatment is a strong predictor for treatment response. Patients who failed to achieve a negative HCV RNA at week 12 were unlikely to achieve SVR; therefore, it might indeed be necessary to adjust treatment duration to the individual decay of HCV RNA under therapy, and patients showing a decay but not negative HCV RNA levels at week 12 might benefit from a longer treatment course of 48 weeks. Conversely, patients who achieved negative HCV RNA levels at week 4 of therapy were very likely to achieve an SVR, a finding that might be reassuring to the practitioner and patient to persevere with therapy and limit treatment to 24 weeks. Proceeding as such would apply lessons learned in the setting of chronic HCV infection, where individualized treatment duration according to RVR has been established as standard of care [16] .
Within this study, despite a large patient sample, factor analysis on SVR revealed no influence of virusspecific factors (such as HCV RNA viral load and HCV genotype), surrogates for host-virus interaction (such as ALT and clinically symptomatic hepatitis) or host factors (such as age and status of HIV infection). This is surprising because in the setting of chronic HCV infection, patient age, CD4 + T-cell count, baseline HCV RNA and HCV genotype have all been associated with the odds of achieving SVR [16] . In addition, high ALT and symptomatic hepatitis have been Early virological response (EVR) was defined as negative HCV RNA levels (<600 IU/ml) at week 12 of therapy. Rapid virological response (RVR) was defined as negative HCV RNA levels at week 4 of therapy. Sustained virological response (SVR) was defined as negative HCV RNA levels at 24 weeks after the end of therapy. NPV, negative predictive value; PPV, positive predictive value.
linked to increased odds of spontaneous viral clearance after acute HCV infection, both in HIV-negative [17] and HIV-positive individuals, although for the latter, cohort analyses have reported mixed results [1, 11] . Despite the absence of prognostic factors prior to commencement of therapy, some of these findings might well be explained by the nature of acute HCV infection and HIV coinfection. For instance, it is well known that during the acute phase of HCV infection, levels of HCV RNA might fluctuate before the virus is cleared or chronic infection is established [18] . This might explain why the level of HCV RNA at the start of treatment did not play a decisive role on treatment outcome. Similarly, HCV genotype or level of HCV RNA was not a deterministic factor in another large study on the treatment of acute HCV in HIV-negative individuals [19] . It should be noted that the group of patients who had acquired a genotype 2 or 3 infection was small and, given a larger patient sample, the difference in SVR between patients with genotype 1 or 4 and those with genotype 2 or 3 infections might become statistically significant. Unlike Wiegand et al. [19] who found that an ALT value >500 IU/l was predictive for achieving SVR in HIV-negative patients, in our study, 10 Patients with qualitative HCV RNA available at baseline; repeating an analysis that compared patients with HCV RNA>400,000 IU/ml or >800,000 IU/ml with those below the respective cutoff did not show a statistically significant difference with regards to sustained virological response (SVR).
c Maximum alanine aminotransferase (ALT) is the maximum ALT increase measured in serum at time of diagnosis.
d Symptomatic hepatitis was defined by the presence of typical clinical signs and symptoms of hepatitis (for example, right upper quadrant pain, fatigue, discoloration of stool and urine, nausea and vomiting) at the time of diagnosis.
e Time to treatment is the time between diagnosis and start of treatment. HAART, highly active antiretroviral therapy; PEG-IFN, pegylated interferon; STD, sexually transmitted disease; ULN, upper limit of normal.
no surrogate marker for virus-host interactions was significantly associated with SVR. This might be, in part, explained by a hampered immune response caused by HIV coinfection. An alternative explanation might be that in our study, patients waited for spontaneous clearance prior anti-HCV therapy, whereas in the study by Wiegand et al. [19] , patients were treated immediately after diagnosis. One may speculate, however, that high ALT levels or jaundice is associated with spontaneous clearance rather than with treatment outcome. Surprisingly, HIV-related parameters, such as absolute CD4 + T-cell count, use of highly active antiretroviral therapy and HIV RNA levels were also not associated with treatment outcome. However, in our cohort, only 4 patients had a CD4 + T-cell count <200 cells/µl, whereas the majority (62%) had a CD4 + T-cell count between 200 and 500 cells/µl or >500 cells/µl (34%), which might explain a lack of influence of CD4 + T-cell count on treatment outcome.
In this large cohort study of patients treated in the early phase of HCV infection with PEG-IFN with or without ribavirin therapy, SVR rates of 62% were achieved. These rates are far higher than observed if HCV genotype 1 or 4 infections are treated in HIVpositive individuals during the chronic phase. Ribavirin use or dosage did not affect treatment outcome in our cohort; however, given the limitations on patient numbers and the observational nature of our cohort, this observation must be taken with caution and this question can only be addressed adequately in a large randomized controlled trial. Response to anti-HCV treatment was a strong predictor of treatment outcome. Importantly, patients who had not achieved negative HCV RNA levels by week 12 had <10% chance of achieving an SVR; therefore, it might be beneficial for the respective patient if treatment duration is tailored to treatment response. Urgent prospective studies are needed to determine the optimal treatment regimen and duration of therapy, perhaps taking into account initial virological responses, in this group of patients. Successful treatment of acute HCV infection in HIV-positive men who have sex with men will not only significantly improve subsequent health risks caused by chronic HCV infection in the respective individual, but might also help to contain the epidemic of sexually transmitted acute HCV infections within the homosexual community.
